Abstract:Abstract Abstract 1609 Introduction: Salvage chemotherapy followed by autologous stem cell transplant (ASCT) remains to be the standard treatment for most patients with relapsed and refractory aggressive non- Hodgkin lymphoma(NHL) and Hodgkin lymphoma(HL). However, there are no standard salvage chemotherapy regimens for these patients especially for refractory patients. The combination of gemcitabine, vinorelbine and liposomal-doxorubicin (GVD regimen) had been reported to be effective in patients with relapsed HL (N.L.Bartlett et al. Ann Oncol. 2007).The overall response rate was 70% and the complete remission rate was 19%. The main toxicities were mucositis (23%) and febrile neutropenia (9%). Despite this encouraging result in relapsed HL, it was still unclear whether GVD regimen was effective in recurrent aggressive NHL. Objective: This study aimed to evaluate the efficacy and toxicity of GVD regimen in patients with refractory aggressive NHL and HL. Patients and methods: Patients with aggressive NHL and HL who were relapsed or refractory to at least one salvage chemotherapy regimen were enrolled. The GVD regimen was given as follows: gemcitabine: 1000 mg/m2 intravenous(i.v.)on day 1,vinorelbine: 15 mg/m2 i.v. on day 1≤⪢liposomal-doxorubicin: 25 mg/m2 i.v. on day 1, repeated for 14 days≤®Patients with complete response (CR)or partial response (PR) proceeded to autologous stem cell transplant (ASCT) as consolidation. Results: From 1 May 2006 to 30 August 2008, 35 patients (25 NHL and 10 HL) were enrolled and received 129 cycles of chemotherapy. Twenty patients (57.1%) had been treated with at least 3 chemotherapy regimens before enrollment, and 15 patients (42.9%) had been treated with 2 chemotherapy regimens before. The overall response rate (ORR)was 48.6%(95% CI: 32.0%∼65.1%), with 31.4% CR rate(95%CI: 16.0%∼46.8%)≤®The ORR was higher in patients with HL than in patients with NHL(80.0% vs. 36.0%,p=0.023). The ORR was higher in relapsed patients than in refractory patients(73.3% vs. 30.0%,p=0.013). Sixteen patients (9 NHL and 7 HL) were treated by high dose chemotherapy supported by ASCT. With median follow-up of 16 months (2∼61 months),the median progression free survival(PFS) was 5 months(1∼61 months) and the median survival time was 38 months (2∼61 months). 4-year PFS and 4-year overall survival was 28.1% and 58.2% respectively. The serum LDH level and the sequential ASCT were independent prognostic factors. The survival time in patients treated with subsequent ASCT was significantly longer than those without ASCT (median survival: not reached vs. 21 months, p=0.005). The major toxicity was myelosuppression. The incidence of grade ¢ó/¢ô neutropenia and thrombocytopenia was 34.3% and 5.7% respectively≤®Mobilization of hematopoietic progenitor cell was successful in all the 16 patients. There were no treatment-related deaths. Conclusion: GVD regimen is an effective and well-tolerated salvage regimen both for patients with HL and patients with aggressive NHL. GVD followed by AHST yields promising long-lime survival even in patients who are previously heavily treated. Disclosures: No relevant conflicts of interest to declare.

Efficacy of GDP Regimen on Relapsed and Refractory Intermediate and High Grade Non-Hodgkin Lymphoma

Efficacy Observation of GDP Regimen for Treatment of Relapsed and Refractory Non-Hodgkin Lymphoma

Research on the effect of GDP as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma

Rituximab, Gemcitabine, Cisplatin, and Dexamethasone in Patients with Refractory or Relapsed Aggressive B-cell Lymphoma

Clinical effective observation of gemcitabine cobmined with dexamethasone and cisplatin in treating relapsed or refractory non-Hodgkin's lymphoma

Efficacy of Arsenic Trioxide combined with GDP regimen for patients with aggressive relapsed or refractory non-Hodgkin's lymphoma

Efficacy of DICE (dexamethasone, Etoposide, Ifosfamide, and Cisplatin)Regimen on Recurrent and Refractory Non-Hodgkin's Lymphoma

Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse And/or Refractory Non-Hodgkin's Lymphoma

GDP (gemcitabine, Dexamethasone, and Cisplatin) is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Clinical Study of High Dose Chemotherapy Combined with G-CSF Treating Refractory or Relapsed Non-Hodgkin's Lymphoma

Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Salvage Chemotherapy for Patients with Relapsed or Refractory Peripheral T Cell Lymphoma—not Otherwise Specified

[Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma]

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study

Clinical Study on Palonosetron Combined with GDP Regimen in Treatment of Elderly Patients with Relapsed Non-Hodgkin's Lymphoma

Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal-Doxorubicin (gvd) As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma

Promising Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal Doxorubicin (GVD) in 14-Day Schedule As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin’s Lymphoma and Aggressive Non-Hodgkin’s Lymphoma

GemOx±R Regimen for the Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

[Preliminary Study on DHAP Regimen for Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma].

Comparative Study of R-GemOx and RICE Regimens as Second-line Treatments for Refractory or Relapsed DLBCL

[Clinical Observation for NAPD Regimen in the Treatment of 67 Cases of Recurrent Refractory Non-Hodgkin's Lymphoma].

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12